Free Trial
LON:RENE

ReNeuron Group (RENE) Share Price, News & Analysis

ReNeuron Group logo

About ReNeuron Group Stock (LON:RENE)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
3.38
3.38
52-Week Range
N/A
Volume
177,373 shs
Average Volume
578,249 shs
Market Capitalization
£1.93 million
P/E Ratio
N/A
Dividend Yield
0.76%
Price Target
N/A
Consensus Rating
N/A

Company Overview

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Remove Ads
Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

RENE Stock News Headlines

Brace Yourself for Jeff Bezos’ “Amazon Helios”
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.
ReNeuron Group PLC RENE
See More Headlines

RENE Stock Analysis - Frequently Asked Questions

ReNeuron Group plc (LON:RENE) posted its earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($50.20) by $14.30.

Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR) and Sirius Minerals (SXX).

Company Calendar

Last Earnings
7/20/2020
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Trading
Current Symbol
LON:RENE
CIK
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-5,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£783,000.00
Price / Cash Flow
0.61
Book Value
GBX 4 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£1.93 million
Optionable
Not Optionable
Beta
0.83
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (LON:RENE) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners